Targeting HIV Where it Hurts

  • Tomas Hanke, PhD, MSc

    • Professor of Vaccine Immunology, University of Oxford
    • Distinguished Professor Kumamoto University

Targeting HIV Where it Hurts

Presentation Slides

  • Targeting HIV-1 Where It Hurts
  • Even in the broader context of increasing antiretroviral treatment & prevention, HIV-1 vaccine is the best solution and likely key to ending the epidemic
  • Our Aim: To Induce Effective Cytotoxic T Lymphocytes (CTL)
  • More of The Same CTL Will Not Work
  • The Biggest Challenges to Both T- and B-Cell Vaccine Development Are  HIV-1 Diversity and Escape
  • Ways to Tackle Variability
  • Ways to Tackle Variability
  • Our Strategy Is To Focus T Cells on the Functionally Conserved Protein Regions
  • The 1st Generation HIVconsv Alternating Conserved Clade Consensus
  • Clinical Development of The First Generation
  • HIV-CORE 002
  • HIV-CORE 002 (Dorrell) Healthy, HIV-1/2-Negative Adults in Oxford
  • HIV-CORE 002 (Dorrell) HIVconsv in HIV-1-negative Adults in Oxford
  • Identification of Novel, In-natural-infection Subdominant  CD8 T-cell Epitopes
  • HIV-CORE 004
  • HIV-CORE 004 (Jaoko) HIV-1/2-Negative Adults in Nairobi, Kenya
  • HIV-CORE 004 High Magnitude T-cell Responses  Fresh IFN-γ ELISPOT Assay
  • HIV-CORE 004 Breadth at Peak Fresh IFN-γ ELISPOT Assay
  • In Vitro Virus Inhibition Assay
  • HIV-CORE 004 – Broad HIV Inhibition
  • Clinical Development of The First Generation Alternating Conserved Clade Consensus
  • BCN 01 & BCN 02-ROMI
  • BCN 01 (Mothe & Brander) ChAdV63.HIVconsv and MVA.HIVconsv
  • BCN 02 (Mothe & Brander) ChAdV63.HIVconsv and MVA.HIVconsv
  •  BCN 02 (Mothe & Brander)
  •  Better Control of Viremia BCN 02 (Mothe & Brander)
  • Correlations?? BCN 02 (Mothe & Brander)
  • BCN 02 Conclusions
  • RIVER (Fidler) ChAdV63.HIVconsv and MVA.HIVconsv
  • Conclusions for The 1st Generation HIVconsv
  • The Improved 2nd Generation tHIVconsvX conserved mosaic
  • The Conserved-Mosaic Immunogens (Inserts)
  • Vector Delivery
  • The tHIVconsvX Vaccines The Second Generation Conserved Mosaic
  • Expression of tHIVconsvX Proteins from Vaccines
  • Equivalent immunogenicity to the 1st generation in BALB/c mice
  • ChAdOx1 prime-MVA boost is highly immunogenic
  • Magnitude and breadth of CD8+ T-cell responses to tHIVconsvX correlate with low pVL and high CD4+ cell counts
  • Clinical Plans for The Second Generation  tHIVconsvX Vaccines
  • Boats
  • A child holding a peace of tire cover
  • Couple children and a house
  • People at the shore
  •    ACKNOWLEDGEMENTS
  • BCN 01 & 02
  •  BCN 02 Participants ChAdV63.HIVconsv and MVA.HIVconsv
  • BCN 02 Safety ChAdV63.HIVconsv and MVA.HIVconsv